Abstract
Dual anti-platelet therapy remains a cornerstone in the management of patients suffering from acute coronary syndromes (ACS). The combination of aspirin and clopidogrel has been shown to result in significant reductions in cardiovascular end points including recurrent infarction and death in several randomised control trial of patients with ACS. However, many patients still experience ischaemic events on the combination of aspirin and clopidogrel. Aspirin is a relatively weak anti platelet agent. Clopidogrel is a pro drug that required activation by hepatic metabolism and hence its onset of action is delayed; there is genetic variation in the clinical response to the drug, the platelet inhibition is irreversible and no intravenous form is available. Consequently new anti-platelet agents have been developed to address the short falls of this combination therapy. This paper discusses existing anti-platelet regimes and focuses on novel antiplatelet agents that are currently under clinical evaluation.
Keywords: Acute coronary syndrome, aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, elinogrel, vorapaxar, atopaxar
Cardiovascular & Hematological Disorders-Drug Targets
Title: Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds
Volume: 11 Issue: 2
Author(s): F. A. Syed, J. H.N. Bett and D. L. Walters
Affiliation:
Keywords: Acute coronary syndrome, aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, elinogrel, vorapaxar, atopaxar
Abstract: Dual anti-platelet therapy remains a cornerstone in the management of patients suffering from acute coronary syndromes (ACS). The combination of aspirin and clopidogrel has been shown to result in significant reductions in cardiovascular end points including recurrent infarction and death in several randomised control trial of patients with ACS. However, many patients still experience ischaemic events on the combination of aspirin and clopidogrel. Aspirin is a relatively weak anti platelet agent. Clopidogrel is a pro drug that required activation by hepatic metabolism and hence its onset of action is delayed; there is genetic variation in the clinical response to the drug, the platelet inhibition is irreversible and no intravenous form is available. Consequently new anti-platelet agents have been developed to address the short falls of this combination therapy. This paper discusses existing anti-platelet regimes and focuses on novel antiplatelet agents that are currently under clinical evaluation.
Export Options
About this article
Cite this article as:
A. Syed F., H.N. Bett J. and L. Walters D., Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds, Cardiovascular & Hematological Disorders-Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187152911798347007
DOI https://dx.doi.org/10.2174/187152911798347007 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Childhood Systemic Lupus Erythematosus: New and Old Treatments
Current Pediatric Reviews Atrial Fibrillation in Heart Failure: An Innocent Bystander?
Current Cardiology Reviews Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Current Molecular Medicine Co-administration of Phycocyanobilin and/or Phase 2-Inducer Nutraceuticals for Prevention of Opiate Tolerance
Current Pharmaceutical Design Role of Citicoline in Promoting the Repair of Acute Peripheral Nerve Injury in Rat Models
Neuroscience and Biomedical Engineering (Discontinued) Progression and Disruption of Advanced Atherosclerotic Plaques in Murine Models
Current Drug Targets Central Insulin and Insulin-Like Growth Factor-1 Signaling - Implications for Diabetes Associated Dementia
Current Diabetes Reviews Bio Molecular Considerations in Major Depression and Ischemic Cardiovascular Disease
Central Nervous System Agents in Medicinal Chemistry Repurposing of Chemotherapeutics to Combat COVID-19
Current Topics in Medicinal Chemistry Diabetes, Hyperglycemia and Accelerated Atherosclerosis: Evidence Supporting a Role for Endoplasmic Reticulum (ER) Stress Signaling
Cardiovascular & Hematological Disorders-Drug Targets Editorial (Thematic Issue: G-protein Coupled Receptors in Vascular Biology: Implication in Health and Disease)
Current Vascular Pharmacology The Structure-property Relationships of GPCR-targeted Drugs Approved between 2011 and 2021
Current Medicinal Chemistry Whole-Brain Volume CT Angiography can Effectively Detect Early Ischemic Cerebrovascular Diseases
Current Medical Imaging Transcranial Direct Current Stimulation for Treatment of Alzheimer’s Disease: A Systematic Review of Randomized Clinical Trial
Current Psychiatry Reviews Angiotensin Peptides as AT2 Receptor Agonists
Current Protein & Peptide Science Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications
Current Pharmaceutical Design Impact and Therapeutic Potential of PPARs in Alzheimers Disease
Current Neuropharmacology The Large and Growing Burden of Stroke
Current Drug Targets The Role of Mitochondria in Brain Aging and the Effects of Melatonin
Current Neuropharmacology Is Mania the Hypertension of the Mood? Discussion of A Hypothesis
Current Neuropharmacology